QuellTX
Paul S Carter has extensive work experience in the pharmaceutical industry. Paul S started their career at GlaxoSmithKline in 1989, where they held various roles including Group Leader & Manager and Senior Scientific Investigator. During their time at GlaxoSmithKline, Paul worked for over 30 years until May 2020. In May 2020, they joined Quell Therapeutics as the Director and Head of Vector Processing.
Paul S Carter attended The University of Manchester from 1986 to 1989, where they obtained a BSc degree in Biochemistry & Molecular Biology.
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.